Vesicular stomatitis virus-killing tumor cells-Brain Case ()
Vesicular stomatitis virus, a versatile viral vector tool
Vesicular stomatitis virus (VSV) is a non-pathogenic, enveloped, negative-sense RNA rhabdovirus that mainly infects rodents, cattle, pigs, and horses, etc. Low, only individual cases of infection among animal keepers and laboratory personnel. Symptoms are mild or asymptomatic after infection.
VSV can infect almost all types of cells, but cannot initiate productive infection in healthy cells due to type I interferons (Interferons, IFN)-mediated antiviral responses. However, defects in IFN signaling often coincide with tumorigenesis [2-3]. Therefore, VSV is able to infect and selectively destroy cancer cells with minimal damage to normal cells, and at the same time, the low anti-VSV immunity of the general population makes it an ideal oncolytic virus therapeutic agent [4].
The full length of the VSV genome is 11161nt, and it encodes five proteins sequentially from the 3' end to the 5' end: nucleocapsid protein (Nucleocapsid Protein, N), phosphoprotein (Phosphor Protein, P), matrix protein (Matrix Protein, M), sugar Protein (Glycol Protein, G) and large polymerase protein (Large Polymerase Protein, L) [5]. The G protein on its envelope initiates the infection process of the virus by binding to a variety of molecules widely present on the surface of the cell membrane [6]. M proteins have been shown to suppress innate antiviral responses and alter host transcriptional machinery, ultimately forcing tumor cells to undergo apoptosis [7]. The extensive cell tropism of VSV is based on the G protein. In order to improve the safety and selectivity of the oncolytic vector of VSV, it is usually replaced by membrane proteins of other viruses [8].
Advantages and limitations of VSV as an oncolytic virus
In 2000, Stojdl et al. [9] confirmed the potential of VSV as an oncolytic virus for the first time. They found that VSV could significantly inhibit the growth of melanoma in nude mice, but had little effect on normal tissue cells. Subsequently, the oncolytic properties of VSV were also confirmed in a variety of tumor models [10]. VSV has many advantages as an oncolytic virus:
(1) The replication cycle is short, and it only takes 2 to 3 hours from infection to the production of progeny viruses, and can produce high-titer progeny viruses in a short period of time;
(2) G protein-mediated recognition of the infection mechanism enables VSV to have a wide range of tissue tropism and can target a variety of cancer cells;
(3) The probability of human beings being naturally infected with VSV is extremely low, and most organisms do not have antibodies against VSV;
(4) VSV can replicate normally under hypoxic conditions in the tumor microenvironment. exert its tumor killing effect[11];
(5) The virus genome is small, and its reverse genetics research is relatively mature, and it is easy to carry out directional transformation.
The development direction of VSV oncolytic virus
Although VSV has many advantages in tumor therapy, wild-type VSV still has many defects, which is why it needs to be further modified and optimized. The first is the safety issue, mainly manifested in the potential neurotoxicity of VSV. A large number of studies have confirmed the intracranial administration of VSV in rodent models [12], nasal administration [13], intravascular administration [14] and Neuropathy caused by intraperitoneal administration [15], and severe neurotoxicity has also been observed in the thalamus of primates [16]; secondly, the short residence time of the virus in the body affects the oncolytic effect. Multiple administrations are often required in oncolytic therapy, but VSV-G protein can easily cause the body to develop adaptive immunity. When repeated administration, a large number of neutralizing antibodies against VSV in the body will cause VSV to be quickly cleared and fail to reach the goal. To achieve the ideal therapeutic effect, so the research at this stage is devoted to improving the anti-tumor activity and safety of rVSV.
Reduce neurotoxicity and improve safety
Modification of key protein genes of VSV The neurotoxicity of wild-type VSV is mainly related to the cell-killing effect of its M protein and the neurotropism of its G protein. The modification of these two protein genes is the main direction to reduce the neurotoxicity of VSV. Studies have shown that deleting the 51st amino acid methionine on the VSV-M protein (VSVrM51) or replacing it with arginine (rM51R-M) can relieve the inhibitory effect of the M protein on the expression of interferon in infected cells, thereby Improve the safety of the virus in normal tissue cells [17-18].
Janelle et al[19] found that the G protein mutant virus strains of VSV (G5, G5R, G6 and G6R) can achieve similar effects to the M protein mutation (rM51R-M), that is, the expression of interferon is increased and the neurotoxicity is significantly weakened; Roberts [20] reduced the replication ability of VSV in the nervous system by truncating the G protein from the 29th amino acid to the ninth amino acid (CT9) or the first amino acid (CT1); Duntsch et al. [21] In the study, the recombinant VSV vector (rVSV-rG) with the deleted G protein gene was used to package virus particles with single cycle replication in cells transiently expressing VSV-G. The killing effect of glioma was no less than that of wild-type VSV.
Prolong the retention time of VSV in vivo
During the process of infecting and killing tumor cells, oncolytic viruses will also cause the body's immune response to the virus itself. Circulating antibodies in the body, non-specific host proteins or complement proteins neutralize virus particles, which will cause them to be quickly eliminated. Clearance will ultimately affect the effect of oncolytic therapy.
At present, there are many strategies, the first is to use cell carrier delivery, aptamer technology, PEG covalent modification, etc., to temporarily isolate VSV before reaching the tumor site, thereby reducing the contact between VSV and neutralizing antibodies in the blood circulation and being non-specific. Neutralization of host proteins or complement proteins to prevent the virus from being cleared prematurely by the immune system. Tesfay et al. [22] confirmed that PEGylation of VSV effectively prolongs the half-life of the virus in mice by passive immunization with VSV neutralizing antibodies. The second strategy is to make it more conducive to the replication of VSV by regulating the immune microenvironment in vivo. Muik et al. [23] used chimeric virus to replace VSV-G with LCMV-G, which is not easy to induce neutralizing antibody production. The chimeric virus formed can effectively reduce the production of neutralizing antibody; VSV prepared by Altomonte et al. [24] Recombinant virus VSV-gG can secrete a broad-spectrum chemokine-binding protein, equine herpesvirus type 1 glycoprotein (gGEHV-1), and the introduction of gGEHV-1 can significantly reduce tumor in a rat model of hepatocellular carcinoma NK cells and NKT cells in the microenvironment can greatly increase the virus titer in the tumor and thus improve the therapeutic effect; similarly, Wu et al[25] proved that the recombinant virus VSV (MΔ51)- M3 for the treatment of multifocal hepatocellular carcinoma in rats can reduce the accumulation of NK cells and neutrophils in the lesion, thereby increasing the virus titer and oncolytic effect in the tumor.
Enhance the direct killing effect of VSV on tumor cells
To enhance the direct killing effect of VSV on tumor tissue, currently proven effective methods include integrating tumor suppressor genes, suicide genes, enhancing the infiltration effect of VSV on tumor tissue, and combining other treatment methods.
(1) Integrate tumor suppressor genes. p53 is an important tumor suppressor gene in the body. It can effectively inhibit the occurrence and development of tumors by regulating cell cycle signaling pathways to mediate DNA repair, cell senescence, apoptosis, and immune activation [26], and has been used in a variety of oncolytic virus combined therapy.
(2) Integration of suicide genes. The integration of the suicide gene can not only enhance the lethality of VSV to infected tumor cells, but also enable VSV to kill surrounding uninfected tumor cells through the gap junction between cells, which is a very effective way to enhance the lethality of tumor cells. effective strategy. TK/GCV is a suicide gene system widely used in the field of gene therapy. The non-toxic prodrug ganciclovir (GCV) can be phosphorylated by herpes simplex virus thymonic kinase (HSV-TK) to its diphosphate and Three: Phosphate metabolites, which mediate tumor cell apoptosis by inhibiting host cell DNA polymerase activity, and effectively induce the activation of tumor-specific killer T cells [27].
Enhance the infiltration ability of VSV in tumor tissue. Ebert et al[28] inserted the fusion protein (NDV/F) mutant L289A gene of Newcastle disease virus (NDV) into the VSV genome, and the constructed recombinant VSV could induce tumor cells to grow under neutral pH conditions. Membrane fusion of the drug induces the formation of syncytia, thereby accelerating the spread of the virus in the tumor, effectively improving its killing ability against human and mouse hepatocellular carcinoma, and animal experiments have also shown good therapeutic effects.
Induce a stronger tumor-specific immune response
In addition to enhancing the direct killing effect on tumors, the induction of stronger tumor-specific immune responses by VSV is also crucial for the complete cure of tumors.
(1)Integrate immune regulatory cytokine genes. Recombinant VSV encoding genes such as IL-4, IL-12, IL-15, IL-23, IL28, Fl3L, CD40L, etc., which encode immune regulatory cytokines, have been proven to effectively enhance tumor-specific adaptive immune responses in mouse tumor models , it is worth mentioning that the recombinant virus VSV-IEFNB expressing IFNB has shown a strong anti-tumor T cell response in animal experiments [29], and has entered phase I clinical trials.
(2)Integrate tumor-associated antigen genes. It is also an effective way to enhance the anti-tumor immune response by integrating tumor-associated antigen (tumour-associated antigen, TAA) gene to enhance the presentation of TAA in infected tumor cells, thereby promoting the recognition of tumor cells by immune cells.
(3) Combined immune checkpoint inhibitors. In recent years, immune checkpoint inhibitors have occupied an important position in the field of cancer treatment because they can block the inhibitory effect of tumor cells on immune cells and restore the killing function of immune cells. Studies have shown that the combination of VSV-TAA and PD-1 antibody can enhance the therapeutic effect by enhancing Th1 response, and the simultaneous use of PD-1 inhibitor and CTLA-4 inhibitor can even enhance the efficacy of VSV-TAA by enhancing Th17 response [30]. In addition, the combined use of VSV-mIFNβ-NIS and PD-L1 antibody, an increase in tumor-infiltrating CD4+ and CD8+ cells can be observed in a mouse acute myeloid leukemia model, and the therapeutic effect is significantly improved [31].
Figure 2: VSV oncolytic virotherapy can generate anti-tumor immunity due to the viral infection of transformed cells(DOI: 10.2147/OV.S66079).
Note: Tumor reduction is achieved through both direct and indirect mechanisms. Viral replication within tumor cells leads to cytopathic effects and ultimately to the death of infected cells. Likewise, the innate antiviral response of infected cells results in tumor cell death through downstream effects of type I interferon signaling. This is combined with the release of tumor antigens and danger-associated molecular patterns (DAMPs), stimulating the maturation of local dendritic cells. The mature dendritic cells secrete pro-inflammatory cytokines to recruit innate effector cells to mediate tumor killing, and they migrate to tumor-draining and distant lymph nodes to present tumor antigens to tumor-reactive CD8+ T cells. The activated T cells then migrate to the tumor and mediate antigen-specific attacks on tumor cells.
Oral stomatitis oncolytic virus in clinical stage
In recent years, with the continuous development of the VSV oncolytic virus platform, many oncolytic virus recombinant variants based on VSV transformation have emerged, mainly aimed at improving tumor targeting, prolonging the retention time in vivo, and enhancing oncolytic effects. The safety and effectiveness of VSV oncolytic virus for tumor treatment have been improved, and a series of VSV-based oncolytic virus preparations have gradually entered the clinical trial stage.
#
Vector type
Indications
Clinical summary
1
VSV-hIFNB-NIS
Solid tumors
non-small cell lung cancer
neuroendocrine tumors
The aim of this study is to determine the optimal dosage of VSV-IFNB-NIS in combination with pembrolizumab in patients with solid tumors
2
VSV-IFNbetaTYRP1
Thornton
The study investigated the safety and optimal dosage of the modified virus VSYIPNbeaTYRP in treating patients with stage III-IV melanoma. Two genes were modified in the vesicular stomatitis virus (VSV): human interferon B (hIFNbeta), which can protect normal healthy cells from viral infection; and TYRP1, which is primarily expressed in melanocytes and melanoma tumor cells, potentially triggering a strong immune response to kill melanoma tumor cells.
3
VSV-GP
Colon cancer rectal cancer
vSV-GP is a recombinant chimeric vesicular stomatitis virus carrying the envelope glycoprotein (GP) of the visceral non-neurotropic WE-HIPI strain of lymphocytic choriomeningitis virus (LCMV, Arenaviridae) instead of the native vSV glycoprotein (G).
4
VSV-hIFNB-NIS
Malignant solid tumors
The study consists of three parts: a single-agent dose-escalation phase of ITVSV-IFNB-NIS monotherapy, a selection phase of single-agent therapy intravenous regimens, and an expansion phase aimed at exploring the safety, efficacy, MTD, PK, and tumor and biomarker responses of the selected single treatment alone or in combination with avclumab for patients with metastatic colorectal cancer
5
VSV-hIFNB-NIS
Endometrial cancer
This phase trial investigated the adverse effects and optimal dose of Vesicular stomatitis virus-human interferon beta-NIS (VSV-hIFNB-NIS) with or without transporter in combination with or without phospho-lutetinib for the treatment of stage IV or recurrent endometrial cancer patients. VSV-hIFNB-NIS limits its ability to spread to tumor cells. It also contains a gene for a protein called NIS, which helps the body concentrate iodine, allowing tracking of the virus's whereabouts. VSV-hIFNB-NIS may be able to kill tumor cells without harming normal cells
6
VSV-hIFNB-NIS
Multiple myeloma lymphoma
This phase trial investigated the optimal dose and adverse effects of recombinant vesicular stomatitis virus carrying human NIS and IFNB genes (VSV-hIFNB-sodium iodide symporter NIS) in combination with or without phospholipase-tyrosine kinase inhibitor for the treatment of multiple myeloma, acute myeloid leukemia, or T-cell lymphoma patients. VSV-hIFNB-NIS may be able to kill cancer cells without harming normal cells. Phospho-lutetinib can inhibit the growth of tumor cells by blocking some enzymes needed for cancer cell growth. Combining VSV-hIFNB-NIS with phospho-lutetinib may provide better treatment for multiple myeloma, acute myeloid leukemia, and T-cell lymphoma
VSV has achieved certain results in the field of oncolytic viruses and has a very broad application prospect. VSV also exhibits various advantages as a therapeutic platform, such as high immunogenicity, relatively easy transgene insertion into its genome, easy management, and extensive tropism However, in order to achieve tumor cure and even prevent recurrence, more effective treatment strategies need to be explored. Therefore, in addition to obtaining recombinant VSV strains with better therapeutic effects through transformation, exploring the combination of recombinant VSV oncolytic virus with immune checkpoint inhibitors, targeted therapy drugs and other therapeutic methods is also a research method with development potential.
Brain Case VSV Product List
Product No.
Product Name
Illustration
BC-VSV-Vs03
VSV-EYFP
anterograde, Green
BC-VSV-Vs13
VSV-mCherry
anterograde, Red
BC-VSV-Vs28
VSV-WT
Wild type, No color
BC-VSV-Vs31
VSV-ΔG-EYFP
Transformable pseudoviruses and oncolytic viruses
BC-VSV-Vs33
VSV-ΔG
Functional components can be added and
Transformable pseudoviruses and oncolytic viruses
If you are interested in the application of oncolytic viruses and would like to customize personalized oncolytic and evaluation plans, feel free to contact us at BD@ebraincase.com
literature citation 1. Drolet BS, Stuart MA, Derner JD. Infection of Melanoplus sanguinipes grasshoppers following ingestion of rangeland plant species harboring vesicular stomatitis virus. Applied and Environmental Microbiology. 2009;75(10):3029-3033. doi:10.1128/AEM.02368-08
2. Ayala-Breton C, Barber GN, Russell SJ, Peng KW. Retargeting Vesicular Stomatitis Virus Using Measles Virus Envelope Glycoproteins. Human Gene Therapy. 2012;23(5):484-491. doi:10.1089/hum.2011.146
3. Jebar AH, Vile RG, Melcher AA, Griffin S, Selby PJ, Errington-Mais F. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology. 2015;96(7):1533-1550. doi:10.1099/vir.0.000098
4. Barber GN. VSV-tumor selective replication and protein translation. Oncogene. 2005;24(52):7710-7719. doi:10.1038/sj.onc.1209042
5. Banerjee AK. The transcription complex of vesicular stomatitis virus. Cell. 1987;48(3):363-364. doi:10.1016/0092-8674(87)90184-x
6. Johannsdottir HK, Mancini R, Kartenbeck J, Amato L, Helenius A. Host Cell Factors and Functions Involved in Vesicular Stomatitis Virus Entry. Journal of Virology. 2009;83(1):440-453. doi:10.1128/jvi.01864-08
7. Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. Journal of Virology. 2003;77(8):4646-4657. doi:10.1128/jvi.77.8.4646-4657.2003
8. Hastie E, Cataldi M, Marriott I, Grdzelishvili VZ. Understanding and altering cell tropism of vesicular stomatitis virus. Virus research. 2013;176(0). doi:10.1016/j.virusres.2013.06.003
9. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature medicine. 2000;6(7):821-825. doi:10.1038/77558
10. Melzer M, Lopez-Martinez A, Altomonte J. Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil.” Biomedicines. 2017;5(4):8. doi:10.3390/biomedicines5010008
11. Connor JH, Naczki C, Koumenis C, Lyles DS. Replication and Cytopathic Effect of Oncolytic Vesicular Stomatitis Virus in Hypoxic Tumor Cells In Vitro and In Vivo. Journal of Virology. 2004;78(17):8960-8970. doi:10.1128/jvi.78.17.8960-8970.2004
12. Dal Canto MC, Rabinowitz SG, Johnson TC. Status spongiousus resulting from intracerebral infection of mice with temperature-sensitive mutants of vesicular stomatitis virus. British Journal of Experimental Pathology. 1976;57(3):321-330. Accessed November 29, 2022. https://pubmed.ncbi.nlm.nih.gov/182197/
13. Plakhov IV, Arlund EE, Aoki C, Reiss CS. The Earliest Events in Vesicular Stomatitis Virus Infection of the Murine Olfactory Neuroepithelium and Entry of the Central Nervous System. Virology. 1995;209(1):257-262. doi:10.1006/viro.1995.1252
14. Shinozaki K, Ebert O, Suriawinata A, Thung SN, Woo SLC. Prophylactic Alpha Interferon Treatment Increases the Therapeutic Index of Oncolytic Vesicular Stomatitis Virus Virotherapy for Advanced Hepatocellular Carcinoma in Immune-Competent Rats. Journal of Virology. 2005;79(21):13705-13713. doi:10.1128/jvi.79.21.13705-13713.2005
15. Schellekens H, Smiers-de Vreede E, de Reus A, Dijkema R. Antiviral activity of interferon in rats and the effect of immune suppression. The Journal of general virology. 1984;65 ( Pt 2):391-396. doi:10.1099/0022-1317-65-2-391
16. Johnson JE, Nasar F, Coleman JW, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology. 2007;360(1):36-49. doi:10.1016/j.virol.2006.10.026
17. Gray Z, Tabarraei A, Moradi A, Kalani MR. M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells. Molecular Biology Reports. 2019;46(3):3371-3379. doi:10.1007/s11033-019-04799-3
18. Day GL, Bryan ML, Northrup SA, Lyles DS, Westcott MM, Stewart JH. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer. Journal of Surgical Research. 2020;245:127-135. doi:10.1016/j.jss.2019.07.032
19. Janelle V, Brassard F, Lapierre P, Lamarre A, Poliquin L. Mutations in the Glycoprotein of Vesicular Stomatitis Virus Affect Cytopathogenicity: Potential for Oncolytic Virotherapy. Journal of Virology. 2011;85(13):6513-6520. doi:10.1128/jvi.02484-10
20. Roberts A, Kretzschmar E, Perkins AS, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. Journal of Virology. 1998;72(6):4704-4711. doi:10.1128/JVI.72.6.4704-4711.1998
21. Duntsch CD, Zhou Q, Jayakar HR, et al. Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice—glioma coculture model. Journal of Neurosurgery. 2004;100(6):1049-1059. doi:10.3171/jns.2004.100.6.1049
22. Tesfay MZ, Kirk AC, Hadac EM, et al. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. Journal of Virology. 2013;87(7):3752-3759. doi:10.1128/JVI.02832-12
23. Muik A, Stubbert LJ, Jahedi RZ, et al. Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency. Cancer Research. 2014;74(13):3567-3578. doi:10.1158/0008-5472.CAN-13-3306
24. Altomonte J, Wu L, Chen L, et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2008;16(1):146-153. doi:10.1038/sj.mt.6300343
25. Wu L, Huang T, Meseck M, et al. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Human Gene Therapy. 2008;19(6):635-647. doi:10.1089/hum.2007.163
26. Kannan K, Amariglio N, Rechavi G, et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene. 2001;20(18):2225-2234. doi:10.1038/sj.onc.1204319
27. Yamamoto S, Suzuki S, Hoshino A, Akimoto M, Shimada T. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Therapy. 1997;4(2):91-96. https://pubmed.ncbi.nlm.nih.gov/9080117/
28. Ebert O, Shinozaki K, Kournioti C, Park MS, García-Sastre A, Woo SLC. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Research. 2004;64(9):3265-3270. doi:10.1158/0008-5472.can-03-3753
29. Obuchi M, Fernandez M, Barber GN. Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity. Journal of Virology. 2003;77(16):8843-8856. doi:10.1128/jvi.77.16.8843-8856.2003
30. Cockle JV, Rajani K, Zaidi S, et al. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-Oncology. 2016;18(4):518-527. doi:10.1093/neuonc/nov173
31. Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood. 2016;127(11):1449-1458. doi:10.1182/blood-2015-06-652503
